The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource Utilization
A recently published systematic literature review synthesizes evidence from 50 publications across 43 studies on the economic burden NSCLC in locally advanced (stage IIIB/C) and metastatic (stage IV) non-small cell lung cancer, highlighting high healthcare resource utilization (HCRU) rates includ...
Biopharma Ecosystem Competitiveness: Post-COVID Challenges and Opportunities
Biopharma Ecosystem Competitiveness in Global Race
A new EFPIA analysis compares bioph...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
MFN Policy Effectiveness in Countering Freeloading Claims
The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...